E
Palvella Therapeutics, Inc. PVLA
$23.44 -$1.13-4.60% NASDAQ
Recommendation
Prev Close
$24.57
Volume
211,210
Avg Vol (90D)
65,078
Market Cap
$270.73M
Dividend & Yield
--
52-Week Range
$11.17 - $29.27
P/E (TTM)
--
EPS (TTM)
-$2.91
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Why These 15 Healthcare Stocks Are Surging in 2025
4/29/2025 - Insider Monkey
Nantahala Capital Management LLC Buys Shares of 250,062 Palvella Therapeutics (NASDAQ:PVLA)
4/28/2025 - Ticker Report
Blue Owl Capital Holdings LP Takes $3 Million Position in Palvella Therapeutics (NASDAQ:PVLA)
4/26/2025 - MarketBeat
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
4/23/2025 - Globe Newswire
Palvella Therapeutics (PVLA, $25.45) entered Uptrend as Momentum indicator ascends above 0 level on Apr 21, 2025
4/22/2025 - Tickeron - Stocks
Palvella Therapeutics (PVLA) Secures Patent for Innovative QTORIN Rapamycin Gel PVLA Stock News
4/22/2025 - GuruFocus
Palvella Therapeutics granted U.S patent for QTORIN Rapamycin
4/22/2025 - The Fly
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations
4/22/2025 - Globe Newswire
Palvella Therapeutics (NASDAQ:PVLA) Given Average Recommendation of "Buy" by Analysts
4/21/2025 - MarketBeat
Palvella Therapeutics (PVLA, $24.4) entered Downtrend as Momentum indicator drops below 0 level on Apr 16, 2025
4/17/2025 - Tickeron - Stocks
Palvella Therapeutics (PVLA, $23.93) entered Uptrend as Momentum indicator ascends above 0 level on Apr 15, 2025
4/16/2025 - Tickeron - Stocks
Palvella Therapeutics (PVLA, $24.44) price moved above its 50-day Moving Average on April 14, 2025
4/15/2025 - Tickeron - Stocks
Palvella Therapeutics (PVLA, $24.44) Stochastic Oscillator left the oversold zone on April 14, 2025
4/15/2025 - Tickeron - Stocks
What is Chardan Capital's Estimate for PVLA FY2025 Earnings?
4/15/2025 - MarketBeat
Independent Chairman of the Board of Palvella Therapeutics George Jenkins Buys 1.4% More Shares
4/14/2025 - Simply Wall St
Palvella Therapeutics (NASDAQ:PVLA) Director Purchases $50,325.00 in Stock
4/12/2025 - Ticker Report
Video: Friday 4/11 Insider Buying Report: HNRG, PVLA
4/11/2025 - Market News Video
Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Chardan Capital
4/11/2025 - MarketBeat
Palvella Therapeutics (PVLA) Showcases Positive Results for QTORIN Rapamycin Gel PVLA Stock News
4/11/2025 - GuruFocus
Palvella Therapeutics announces data on QTORIN rapamycin
4/11/2025 - The Fly
Palvella Therapeutics Announces QTORIN Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
4/11/2025 - Globe Newswire
Financial Contrast: Q BioMed (OTCMKTS:QBIO) versus Palvella Therapeutics (NASDAQ:PVLA)
4/9/2025 - Ticker Report
Palvella Therapeutics initiated with bullish view at Chardan, here's why
4/9/2025 - The Fly
Palvella Therapeutics (PVLA, $20.07) price may climb as it broke lower Bollinger Band on Apr 07, 2025
4/8/2025 - Tickeron - Stocks
Palvella Therapeutics (PVLA, $20.07) price exceeded its 50-day Moving Average on April 07, 2025
4/8/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$14.67M
Net Income (TTM)
-$18.25M
Balance Sheet
Total Assets (Q)
$88.23M
Total Debt (Q)
$11.94M
Total Liabilities (Q)
$25.63M
Book Value Per Share (Q)
$5.69
Cash Flow
Cash from Operations (TTM)
-$10.84M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$87.09M
Net Change in Cash (TTM)
$76.25M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Sep 22 and 26 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-3.78%
30-Day Total Return
-14.76%
60-Day Total Return
80.31%
90-Day Total Return
82.70%
Year to Date Total Return
95.33%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Dec 30, 2024 - $11.17
52-week High
Mar 13, 2025 - $29.27
Valuation
Market Cap
$270.73M - Micro Cap
Enterprise Value
$199.07M
Price/Sales (TTM)
--
Price/Book (Q)
4.32
Dividends and Shares
Shares Outstanding
11.01M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
palvellatx.com
Phone Number
484 253 1461
Address
125 Strafford Avenue
Wayne, PA 19087
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The... more
NASDAQ 04/29/2025 4:00PM Eastern Quotes delayed